Genomic and proteomic insights into hidradenitis suppurativa
A dual pathogenic model of HS involving both epithelial dysfunction and systemic inflammation is supported. The HLA‐DRA association hints at autoimmune overlap, but the proteomic signature which is dominated by innate immune mediators favours an autoinflammatory classification, which may guide future therapeutic strategies and patient stratification ...
Maria Argyropoulou +8 more
wiley +1 more source
First Report of Transient Global Amnesia Associated with Adalimumab: In a Hidradenitis Suppurativa Patient. [PDF]
Hazinedar E +3 more
europepmc +1 more source
Proteomic analysis in hidradenitis suppurativa reveals systemic inflammation in all disease stages
Proteomic profiling reveals systemic inflammation in patients with hidradenitis suppurativa, even in early disease. Distinct mediators (e.g. TGF‐α, OSM, HGF) are elevated early, whereas others correlate with clinical severity (e.g. IL‐6, VEGF‐A, IL‐17A) or disease duration (e.g.
Lotta Sandelin Francke +5 more
wiley +1 more source
Successful bimekizumab retreatment after secondary failure in multi‐biologic‐resistant psoriasis
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nicole Kah Mun Yoong +4 more
wiley +1 more source
Measuring success in HS treatment from the physician's and the patient's perspective
Integrated clinician (HiSCR, IHS4, IHS4‐55, HS‐IGA) and patient (HiSQOL, DLQI) scores, combined with imaging‐based fibrosis and inflammation assessment, redefine treatment success in hidradenitis suppurativa by aligning treat‐to‐target strategies with both inflammatory control and irreversible structural damage.
Georgios Nikolakis +4 more
wiley +1 more source
Topographic Expression of IL-1β and Inflammasome-Associated Proteins in Lesional, Perilesional, and Distant Hidradenitis Suppurativa Skin. [PDF]
Lewandowski M +4 more
europepmc +1 more source
Updated S2k hidradenitis suppurativa (HS) guidelines provide expert consensus on diagnosis, assessment and comorbidities. Expanded substantially since the 2015 version, they reflect rapid growth in HS literature and aim to improve generalist‐level patient care through evidence‐informed, consensus‐based guidance.
G. B. E. Jemec +36 more
wiley +1 more source
Male sexual dysfunction associated with TNF-α inhibitors: an indication-stratified global pharmacovigilance analysis. [PDF]
Chu Y, Luo M, Li W, Wang X, Zhou Y.
europepmc +1 more source
Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion
Systematic review of 108 studies with a total of 182 patients with interstitial granulomatous dermatitis (IGD). IGD was frequently associated with systemic conditions or drug exposure. Management includes careful medication review and prompt withdrawal of potential triggers. Corticosteroids (systemic and topical) were commonly effective, while biologic
Francesco Bellinato +4 more
wiley +1 more source
Real-world effectiveness of tofacitinib in monotherapy or in combination with csDMARDs in patients with rheumatoid arthritis: A collaboration between Dutch registries (TOFADUDAP study). [PDF]
Nevins IS +8 more
europepmc +1 more source

